ArticleIndian journal of dermatology
Efficacy of Tranexamic acid Microneedling versus Intradermal Injection of Tranexamic Acid in the Treatment of Melasma - A Randomised Controlled Trial.
Article in Indian journal of dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Melasma is a pigmentary disorder that typically appears on the face. Given its tendency to relapse, resistance to treatment and significant impact on social and emotional well-being, melasma poses considerable challenges. Objectives: To compare the effectiveness and adverse effects of tranexamic acid (TXA) in reducing modified Melasma Area and Severity Index (mMASI) scores when given along with microneedling versus intradermal injections in the treatment of melasma. Materials and Methods: This was a hospital-based randomised controlled study conducted in the outpatient Department of Dermatology, Venereology and Leprosy, Aarupadai Veedu Medical College, among patients with melasma, between November 2022 and April 2024. In Group A ( Results: The baseline characteristics of the study groups did not vary significantly by age (in years), gender, Fitzpatrick skin type, precipitating factors, clinical type of melasma, and pattern of melasma. Both groups showed significant reduction in mMASI scores from baseline to 20 weeks (7.1 ± 2.3 to 4.6 ± 0.5 in Group A and 7.0 ± 3.1 to 5.3 ± 0.7 in Group B, respectively). From 12 Conclusion: The study highlights microneedling with TXA as a promising and effective treatment option for melasma, offering substantial clinical improvement and patient satisfaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.